Skip to Content
Top

BY MD Anderson

The following opinion piece includes the collective thoughts of several MD Anderson prevention researchers

Recently, the Food and Drug Administration (FDA) took some long-overdue steps when it announced its proposed regulations on electronic cigarettes.

For the past few years, the booming e-cigarette industry, which saw sales jump from $500 million in 2012 to nearly $2 billion today, has operated with little oversight. The...

BY Laura Sussman

Advancements in imaging have dramatically altered all aspects of cancer care — from diagnosis and treatment to surveillance and prevention...

BY MD Anderson Staff

While many times, the achievements of senior faculty members receive the greatest attention, MD Anderson is also taking steps to highlight...

BY Scott Merville

A newly approved drug for the treatment of chronic lymphocytic leukemia (CLL), studied in clinical trials at MD Anderson, is showing significant promise. In February, the U.S. Food and Drug Administration granted accelerated approval of Imbruvica, for use in previously treated CLL patients.

"Ibrutinib produces durable responses in patients after other treatments have failed, and with very little toxicity. The main side effect...

cancer clinical trials for chronic lymphocytic leukemia

BY MD Anderson Staff

In 2011, the MD Anderson Cancer Center received a $150 million gift — the largest in the history of the institution — from the Khalifa Bin...

BY MD Anderson

The G.H.A. Clowes Memorial Award is the oldest honor bestowed on a researcher by the American Association for Cancer Research. It's been given...

BY MD Anderson

The promise of immunotherapy, drugs that stimulate the body's immune system to fight cancer, can be witnessed by observing the string of development...

BY MD Anderson

Additional presentations of note at this year's American Association for Cancer Research Annual Meeting:

Reclassifying low-grade brain...

BY Scott Merville

The 54th annual meeting of the American Association for Cancer Research opens this morning in San Diego with educational sessions and workshops...